Intra-Cellular Therapies, Inc. (ITCI)
After hours:
| Previous close | 68.80 |
| Open | 68.88 |
| Bid | 70.94 x 200 |
| Ask | 71.03 x 200 |
| Day's range | 68.49 - 71.02 |
| 52-week range | 45.50 - 84.89 |
| Volume | |
| Avg. volume | 978,928 |
| Market cap | 7.497B |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.46 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 91.91 |
ZacksAcadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireIntra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, May 7, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2024. To attend the live con
ZacksWill Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
